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A 44-year-old Japanese woman with systemic lupus erythematosus (SLE) presented to our hospital with abdominal pain.
Radiological and endoscopic examinations led to the diagnosis of diffuse large B-cell lymphoma of the jejunum, which was
subsequently resected. Patients with SLE reportedly have an increased risk of non-Hodgkin lymphoma, as demonstrated by our
patient. Hence, lymphoma should be considered in the differential diagnosis of neoplastic lesions emerging in SLE patients. In
addition, flow cytometry using endoscopically biopsied fragments is useful for the immediate diagnosis of lymphoma, leading to
timely and accurate preoperative staging.
1. Introduction
Systemic lupus erythematosus (SLE) is a multifactorial au-
toimmune disease that affects various organs in the body. SLE
occasionally affects the gastrointestinal tract, leading to bowel
wall thickening, hemorrhage, obstruction, perforation, in-
farction, or pancreatitis owing to serositis and mesenteric
vasculitis [1, 2]. In addition to inflammation, SLE is reportedly
linked to an increased risk of malignant diseases such as
cancers of the esophagus, stomach, hepatobiliary complex,
cervix, vagina/vulva, kidney, bladder, lung, oropharynx, lar-
ynx, skin, and thyroid [3–5]. SLE patients have a particularly
increased risk of lymphoproliferative disorders. Malignant
diseases are one of the major causes of morbidity and
mortality in SLE patients, and prompt diagnosis and treat-
ment are keys to their successful management.
We report a case of an SLE patient who presented with
postprandial abdominal pain. Radiological, endoscopic, and
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pathological examinations led to the diagnosis of diffuse
large B-cell lymphoma in the jejunum. Of note, double
balloon enteroscopy and flow cytometry analysis using
endoscopically biopsied fragments were useful for the im-
mediate diagnosis of lymphoma, leading to timely and ac-
curate preoperative staging.
2. Case Presentation
A 44-year-old Japanese woman presented with postpran-
dial abdominal pain since 2 months. She had been diag-
nosed with SLE at the age of 37 years. +e patient also had
lupus nephritis, Basedow’s disease, steroid diabetes, idio-
pathic thrombocytopenic purpura, and hypertension, for
which she had been taking tacrolimus, azathioprine,
hydroxychloroquine, prednisolone (10mg/day), nifedi-
pine, eplerenone, hydralazine, lansoprazole, propylth-
iouracil, alfacalcidol, and sodium ferrous citrate. She was a
social drinker and an ex-smoker who smoked 30 cigarettes/
day for 10 years. On examination, her body temperature
was 36.7°C, blood pressure was 123/80mmHg, and pulse
rate was 103 bpm. Her height was 148.5 cm and weight was
42.4 kg. Physical examination revealed conjunctival ane-
mia, exophthalmos, enlarged thyroid, and distended ab-
domen with hyperactive bowel sounds, but there was no
palpable mass or tenderness in her abdomen. Laboratory
tests showed decreased values for hemoglobin concentra-
tion (9.0 g/dL) and hematocrit (28.3%). +e C-reactive
protein (4.11mg/dL), erythrocyte sedimentation rate
(104mm/h), and soluble interleukin-2 receptor (779 U/mL)
levels were elevated. +e white blood cells, platelets, lactate
dehydrogenase, creatine phosphokinase, anti-double
stranded DNA IgG antibody, complements, carcinoem-
bryonic antigen, and carbohydrate antigen 19–9 were
within the normal range. Urinalysis revealed proteinuria,
leukocytes (20–29 cells/high power field), and tubular
epithelium. Hematuria was absent.
Computed tomography scanning showed whole circum-
ferential thickening of the jejunum with aneurysmal dilatation,
which is a typical feature of malignant lymphomas of the
intestine (Figure 1). On positron emission tomography scan-
ning, tracer uptake was observed in the thickened intestinal
wall (Figure 2). Double balloon enteroscopy revealed cir-
cumferential ulcer and necrotic debris in the jejunum (Fig-
ure 3). A contrast study during enteroscopy showed dilated
jejunal lumen (Figure 4). Based on the morphology of the
jejunal lesion, we suspected small intestinal lymphoma rather
than cancer. +us, we performed flow cytometry analysis with
2 endoscopically biopsied fragments, as described previously
(Figure 5) [6]. +e κ/λ ratio of CD19+CD20+ cells was 3.3
(53.36/16.39), indicatingmonoclonal proliferation of the B cells
producing the κ light chain.+e isolated cells were negative for
CD5 and CD10 on flow cytometry analysis. Bone marrow
biopsy and cytology revealed no lymphoma cell invasion.
Biopsy of the jejunal lesion showed infiltration of atypical, large
lymphoid cells that were positive for CD20 and BCL2 and
negative for CD3, CD5, CD10, and cMYC (Figure 6). +e cells
were diffusely positive for Ki-67. +e results of in situ hy-
bridization for Epstein–Barr virus-encoded small RNA-1 were
also positive. +e jejunal tumor, which had invaded the
transverse colon, was surgically resected. Lymphadenopathies
of themesenterywere observed intraoperatively. Consequently,
a diagnosis of diffuse large B-cell lymphoma in the jejunum at
stage II1E (large intestine) was made. Chemotherapy with
cyclophosphamide, adriamycin, vincristine, and prednisone
plus rituximab was administered postoperatively.
3. Discussion
Patients with SLE and other rheumatic diseases have an in-
creased risk of malignant diseases, of which lymphoma is the
most common neoplasm [7–9]. A nationwide population-
based study in Taiwan revealed that among the 16,417 patients
with SLE, 512 developed cancers (3.1%), including 34with non-
Hodgkin lymphoma (0.2%) [10]. +e standardized incidence
ratio was the highest for non-Hodgkin lymphoma (4.2, 95%CI:
2.9–5.9) on site-specific cancer risk analysis. A meta-analysis
also showed that the pooled standardized incidence ratio for
non-Hodgkin lymphoma in patients with SLE was 4.93 (95%
CI: 3.81–6.36). SLE is considered to be correlated with an
increased risk of non-Hodgkin lymphoma, and the risk is
estimated to be 4–7 times greater than that in the general
population [7]. In addition, diffuse large B-cell lymphoma is the
most common subtype of lymphoma, accounting for 37–62%
of all lymphomas in SLE patients [11–13]. +erefore, diffuse
large B-cell lymphoma should be considered a probable di-
agnosis when tumorous lesions are found in patients with SLE.
Several mechanisms can be hypothesized in the patho-
genesis of non-Hodgkin lymphoma in SLE patients. First,
chronic inflammation may lead to hyperactivity and pro-
liferation of B lymphocytes, resulting in autonomous,
monoclonal expansion [14]. Second, dysregulation of the
immune systemmay cause a defective clearance of apoptotic
cells [7, 15]. +ird, it has been reported that immunosup-
pressants such as cyclophosphamide are partly responsible
for the increased incidence of lymphoma in patients with
SLE [16]. Fourth, the Epstein–Barr virus infection may be a
common trigger factor for SLE and non-Hodgkin lym-
phoma [10]. Previous studies have revealed that patients
with SLE have an elevated viral load, increased Epstein–Barr
virus mRNA expression, elevated levels of Epstein–Barr
virus-directed antibodies, and decreased cell-mediated im-
munity against the virus when compared to healthy controls
[17]. +e Epstein–Barr virus infection results in the pro-
duction of the viral protein “Epstein–Barr virus nuclear
antigen-1” (EBNA-1). Antibodies against EBNA-1 cross
react with the autoantigens found in SLE, including Ro, Sm
B/B′, and Sm D1 [18]. +us, molecular mimicry may play a
crucial role in the pathogenesis of SLE. Simultaneously, the
Epstein–Barr virus can also promote lymphomagenesis [19].
We believed that the Epstein–Barr virus played a pivotal role
in the development of diffuse large B-cell lymphoma in our
patient because the in situ hybridization for Epstein–Barr
virus-encoded small RNA-1 was positive.
It was also noteworthy that flow cytometry analysis using 2
endoscopically biopsied fragments was useful for the prompt
diagnosis of lymphoma in our patient. Since B-cell lymphomas
typically arise from a massive expansion of a B-cell clone,
2 Case Reports in Gastrointestinal Medicine
neoplastic cells express only 1 class of immunoglobulin light
chain, which is either κ or λ chain. +us, immunoglobulin
light-chain expression can be used as a surrogate marker for
clonality. However, flow cytometry has not been widely used in
routine clinical practice for the diagnosis of gastrointestinal
lymphoma, mainly because an appropriate protocol is absent.
We have recently established lymphocyte isolation techniques
and revealed that light chain expression analysis could be
performed with 2 endoscopic biopsy fragments obtained from
10 patients (6). Although pathological analysis is still a standard
for the diagnosis of lymphoma subtype, flow cytometry analysis
has the advantage of delivering faster results; while several
(a) (b) (c)
Figure 3: Double balloon enteroscopy images. A circumferential ulcer with necrotic debris in the jejunum is shown.
(a) (b)
Figure 1: Computed tomography scanning images. Whole circumferential thickening of the jejunum is shown (arrows) (a), (b).
(a) (b)
Figure 2: Positron emission tomography scanning images. Tracer uptake is observed in the thickened intestinal wall.
Figure 4: A contrast study image during enteroscopy. An irreg-
ularly dilated jejunal lumen is observed (arrows).
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Figure 5: Flow cytometry results. We performed flow cytometry using 2 endoscopically biopsied fragments.+e κ/λ ratio of CD19+/CD20+
cells is 3.3 (53.36/16.39), indicating positive light chain restriction.
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Figure 6: Continued.
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hours are required to obtain the results of flow cytometric
analysis, and histological analysis with immunostaining gen-
erally takes days to weeks. Based on the flow cytometry results
of our patient, we consulted with hematologists on the fol-
lowing day and performed bone marrow aspiration and biopsy
2 days after the endoscopy, resulting in timely preoperative
diagnosis.
In conclusion, we encountered an SLE patient with
diffuse large B-cell lymphoma in the jejunum. +is case
reinforces that lymphoma should be considered in the
differential diagnosis of neoplastic lesions emerging in SLE
patients. Moreover, flow cytometry analysis is useful in
making a timely diagnosis of gastrointestinal lymphoma.
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Figure 6: Pathological images. Infiltration of atypical, large lymphoid cells is seen in the endoscopic biopsy specimens (a): Hematoxylin-
eosin stain. Lymphoma cells are positive for CD20 (b) and BCL2 (c), while they are negative for CD3 (d), CD5 (e), CD10 (f), and cMYC (g).
+e cells are diffusely positive for Ki-67 (h).+e results of in situ hybridization for Epstein–Barr virus-encoded small RNA-1 (EBER) are also
positive (i).
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